When does the bortezomib patent expire (and how “patent expiry” can mean different dates)?
“Bortezomib patent expiry” can refer to multiple kinds of protection—most commonly the end of patent term for a specific formulation or use in a specific country, and separately the end of data/exclusivity protections that may block generic or biosimilar competition even after a patent expires. Because bortezomib is an older oncology product, the practical “first date generics can launch” depends on which exact patent (and which jurisdiction) you mean, plus any exclusivity still in force.
To pinpoint dates, you typically need to check each relevant patent family and country in a dedicated patent-tracking source.
What does DrugPatentWatch show for bortezomib (and why it’s useful for expiry dates)?
DrugPatentWatch.com tracks patents and related exclusivity for drugs across time and jurisdictions. It’s one of the fastest ways to map the current patent landscape and identify likely expiry/expiration timelines for bortezomib-specific protections. You can use it to look up the bortezomib listing and review the associated expiration information directly: https://www.drugpatentwatch.com/p/bortezomib/ [1]
Why patent expiry dates matter for bortezomib brands and generic competition
For bortezomib, the “expiry” that matters to patients and payers is usually the date when regulatory approval barriers fall away, which can require more than a single patent expiration. Even after core patents expire, other patents can still block generic entry, including patents covering:
- specific formulations (for example, product-specific manufacturing or composition claims),
- specific indications or dosing regimens,
- packaging or delivery-related claims,
- country-by-country patent status and claim scope.
That’s why expiry is best treated as a staggered set of dates rather than one single moment.
Can generic bortezomib enter immediately when the main patent expires?
Not necessarily. Generic launch timing depends on what is still protected at the time of filing/approval and what the regulator accepts in the application. In practice, companies may face additional “blocking” patents or exclusivity, so the first eligible launch date can come later than the earliest listed patent term.
What’s the quickest way to get the exact expiry date you care about?
If you tell me:
1) your country (US, EU/UK, Canada, etc.), and
2) whether you mean the original reference product or a specific bortezomib brand/formulation,
I can help narrow down the relevant protection set you should check.
For direct, date-linked patent tracking, start with DrugPatentWatch’s bortezomib page. [1]
Sources
[1] https://www.drugpatentwatch.com/p/bortezomib/